| 0 (0%) | 10-15 12:13 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 25.69 | 1-year : | 30.01 |
| Resists | First : | 22 | Second : | 25.69 |
| Pivot price | 19.73 |
|||
| Supports | First : | 17.19 | Second : | 14.22 |
| MAs | MA(5) : | 19.47 |
MA(20) : | 19.24 |
| MA(100) : | 14.39 |
MA(250) : | 14.27 |
|
| MACD | MACD : | 0.5  |
Signal : | 0.6 |
| %K %D | K(14,3) : | 50.5 |
D(3) : | 53.5 |
| RSI | RSI(14): 55.2 |
|||
| 52-week | High : | 24.66 | Low : | 0.76 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MCRB ] has closed below upper band by 46.7%. Bollinger Bands are 33.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 20.1 - 20.2 | 20.2 - 20.29 |
| Low: | 18.97 - 19.08 | 19.08 - 19.18 |
| Close: | 19.52 - 19.7 | 19.7 - 19.87 |
Wed, 15 Oct 2025
How MCRB stock performs in weak economy - July 2025 Institutional & Safe Investment Capital Preservation Plans - newser.com
Wed, 15 Oct 2025
How MCRB stock performs in weak economy - Quarterly Performance Summary & AI Driven Price Forecasts - newser.com
Tue, 14 Oct 2025
Seres Therapeutics (MCRB) to Present New Phase 1b Trial Data at IDWeek 2025 - GuruFocus
Tue, 14 Oct 2025
Seres Therapeutics Presents 77% BSI Reduction in SER-155 Phase 1b | MCRB Stock News - Stock Titan
Tue, 16 Sep 2025
$MCRB stock is up 10% today. Here's what we see in our data. - Quiver Quantitative
Tue, 09 Sep 2025
All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 12.9 (%) |
| Held by Institutions | 26 (%) |
| Shares Short | 858 (K) |
| Shares Short P.Month | 1,010 (K) |
| EPS | -6.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.06 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -12.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -60 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | -2.93 |
| PEG Ratio | 0 |
| Price to Book value | 5.27 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|